PDL: Roche no longer co-developing daclizumab in asthma, will collaborate on other indications

By Lisa Kerner

Charlotte, N.C., Aug. 30 - PDL BioPharma, Inc. said Roche has discontinued its involvement in the co-development of daclizumab in asthma.

The companies will continue to co-develop daclizumab in transplant maintenance and also proceed with planned phase 2 studies for the transplant indication during 2007.

Biogen Idec, Inc. and PDL are developing daclizumab in multiple sclerosis and indications other than transplant and respiratory diseases.

"We are evaluating opportunities to establish a new collaboration and would need to partner this program in order to further develop daclizumab in asthma," chief executive officer Mark McDade said in a company news release.

"In the meantime, we will redouble our efforts to focus daclizumab development in MS and chronic transplant."

PDL is a biopharmaceutical company located in Fremont, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.